tiprankstipranks
Trending News
More News >
MATERNUS-Kliniken AG (DE:MAK)
XETRA:MAK
Advertisement

MATERNUS-Kliniken AG (MAK) AI Stock Analysis

Compare
0 Followers

Top Page

DE:MAK

MATERNUS-Kliniken AG

(XETRA:MAK)

Rating:43Neutral
Price Target:
€1.00
▼(-11.50% Downside)
The overall stock score reflects significant financial challenges, with persistent losses and high leverage being the most impactful factors. Technical analysis shows a bearish trend, and valuation metrics are weak due to negative earnings and no dividend yield. The lack of earnings call and corporate events data limits further insights.

MATERNUS-Kliniken AG (MAK) vs. iShares MSCI Germany ETF (EWG)

MATERNUS-Kliniken AG Business Overview & Revenue Model

Company DescriptionMATERNUS-Kliniken AG (MAK) is a leading healthcare provider in Germany, specializing in rehabilitation and acute care services. With a focus on high-quality medical treatment and patient-centered care, the company operates several clinics that provide a range of services, including orthopedic rehabilitation, neurological rehabilitation, and psychosomatic therapy. MAK is dedicated to enhancing patient outcomes through innovative therapies and a multidisciplinary approach, positioning itself as a key player in the healthcare sector.
How the Company Makes MoneyMATERNUS-Kliniken AG generates revenue primarily through the provision of healthcare services, which are funded by a combination of health insurance reimbursements and out-of-pocket payments from patients. The company's core revenue streams include inpatient and outpatient rehabilitation services, consultation fees, and specialized treatment programs. Additionally, MAK may benefit from partnerships with health insurance companies, government health programs, and other healthcare organizations that facilitate patient referrals and enhance service offerings. By maintaining high occupancy rates in its clinics and continuously improving service efficiency, the company is able to optimize its earnings and ensure sustainable financial growth.

MATERNUS-Kliniken AG Financial Statement Overview

Summary
The company faces significant financial challenges with persistent losses and high leverage. Despite a slight revenue growth and strong gross profit margin, the negative net profit margin and negative equity highlight financial instability. Improvement in cash flow is a positive sign, but overall, the financial position remains precarious.
Income Statement
45
Neutral
The company has shown a slight revenue growth of 4.87% in the latest year, but it continues to struggle with profitability, evidenced by a negative net profit margin of -11.54% and a negative EBIT margin of -1.62%. The gross profit margin remains strong at 86.65%, indicating efficient cost management at the gross level. However, the persistent negative net income suggests challenges in managing operating expenses and interest costs.
Balance Sheet
30
Negative
The balance sheet reveals significant financial leverage with a debt-to-equity ratio of -2.47, indicating high reliance on debt financing. The negative stockholders' equity suggests financial instability and potential solvency issues. Return on equity is not meaningful due to negative equity, and the equity ratio is negative, highlighting a precarious financial position.
Cash Flow
55
Neutral
Cash flow analysis shows improvement with a free cash flow growth rate of 51.05%, indicating better cash generation capabilities. The operating cash flow to net income ratio of 0.11 suggests that cash flows are not fully covering net losses, but the free cash flow to net income ratio of 0.92 shows a positive trend in cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue108.71M114.00M102.31M106.70M111.44M114.30M
Gross Profit13.45M98.78M87.45M86.98M97.52M97.70M
EBITDA5.66M10.71M4.71M1.71M14.96M13.21M
Net Income-6.88M-13.16M-14.26M-14.08M-2.48M-9.62M
Balance Sheet
Total Assets150.59M139.88M154.38M153.40M165.41M178.63M
Cash, Cash Equivalents and Short-Term Investments3.59M4.94M8.05M5.20M13.58M11.41M
Total Debt186.53M165.41M112.35M170.31M168.99M181.36M
Total Liabilities204.53M206.72M206.49M192.70M193.26M204.03M
Stockholders Equity-55.60M-66.84M-53.76M-39.30M-27.85M-25.41M
Cash Flow
Free Cash Flow9.17M13.86M-1.44M2.33M15.32M11.43M
Operating Cash Flow14.69M15.07M2.52M4.33M17.24M12.17M
Investing Cash Flow-5.53M-1.07M-3.96M-2.00M-1.92M-702.00K
Financing Cash Flow-9.85M-11.68M7.46M-12.76M-12.79M-2.23M

MATERNUS-Kliniken AG Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.13
Price Trends
50DMA
1.25
Negative
100DMA
1.37
Negative
200DMA
1.44
Negative
Market Momentum
MACD
-0.04
Positive
RSI
34.00
Neutral
STOCH
14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MAK, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.25, and below the 200-day MA of 1.44, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.00 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MAK.

MATERNUS-Kliniken AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
€118.80M25.2623.66%0.21%7.53%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
43
Neutral
€23.70M
11.43%7.72%
€141.55M4.0015.78%
€5.82M1.9029.97%
€23.40M11.43
69
Neutral
€249.17M15.6414.61%3.75%7.23%58.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:MAK
MATERNUS-Kliniken AG
1.08
-0.67
-38.29%
GB:0NDG
MEDICLIN
2.86
0.28
10.85%
DE:LIK
Limes Schlosskliniken AG
396.00
20.00
5.32%
DE:EIF
Eifelhoehen-Klinik AG
1.93
0.51
35.92%
DE:JTH0
Gesundheitswelt Chiemgau AG
12.00
0.02
0.17%
DE:M12
M1 Kliniken AG
13.54
-2.39
-15.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 28, 2025